Roche announced the launch of its in-situ hybridization (ISH) in vitro diagnostic test, the Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries accepting the CE Mark.
The test is intended for the qualitative detection of Kappa mRNA and Lambda mRNA in formalin-fixed, paraffin-embedded human bone marrow and lymphoid tissue stained on a BenchMark IHC/ISH instrument using chromogenic ISH and visualized using light microscopy.
Roche said that the new ISH test is designed to aid pathologists in differentiating a B-cell malignancy from a normal reactive response to an infection. B-cell lymphoma accounts for approximately 85% of non-Hodgkin lymphoma cases, the company noted.
Roche added that the assay can assess small biopsies and reduce the need for additional biopsies, especially in situations where lymphoma was not originally suspected.
